N-substituted spiropiperidine compounds as ligands for ORL-1 receptor
US6869960B2 · kind B2 · utility
24Cited by
0References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 23, 2003 |
| Grant date | Mar 22, 2005 |
| Priority date | — |
| Expiry date | Jan 23, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound of the formula: or a pharmaceutically acceptable salt, ester or ether thereof, wherein R1 through R12 are independently hydrogen or the like; X1 and X2 are independently CH2 or the like; R13 is hydrogen or the like; or R12 and R13 taken together with three ring atoms of the quinoline ring separating said substituents form a heterocyclic ring; R14 and R15 are hydrogen or the like or these groups taken together form oxo; and the dotted line represents a single or double bond. These compounds are ligands for ORL-1 receptor and especially are antagonists for said receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.